Clinical Trial Update: Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on eribulin mesylate in patients with locally advanced or metastatic urothelial carcinoma of the bladder, including those with kidney dysf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma of the Bladder

Drugs mentioned

• Halaven (eribulin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING